Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02727803
Title	Personalized NK Cell Therapy in CBT
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	M.D. Anderson Cancer Center
Indications	chronic myeloid leukemia Hodgkin's lymphoma myelodysplastic/myeloproliferative neoplasm acute leukemia myelodysplastic syndrome non-Hodgkin lymphoma chronic myelomonocytic leukemia chronic lymphocytic leukemia acute lymphoblastic leukemia acute myeloid leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma multiple myeloma
Therapies	anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells
Age Groups:	child \| adult \| senior
Covered Countries	USA